CTLA4 and common variable immunodeficiency: Data from single-center or nationwide study revealed that the prevalence of pathogenic CTLA-4 or LRBA mutations among subjects with a CVID/CVID-like diagnosis ranges between 1.7–20.8% and 0.9–7.2%, respectively [4,22].